GlassScriptPhysician profile
Zhao MD Han
NPI 1134652852
$7,053.19
in general payments reported to CMS, 2019-2025
30 companies · $1,614 in 2025
The $1,614 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $356 · 2021: $1,184 · 2022: $1,315 · 2023: $1,175 · 2024: $1,409 · 2025: $1,614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,197.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,317.54 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $876.10 | 2021-2025 | Jardiance |
| Lilly USA, LLC | $674.88 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $595.07 | 2020-2025 | Farxiga, Breztri |
| Amgen INC. | $581.16 | 2020-2025 | Evenity, Repatha, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $282.35 | 2021-2024 | |
| Radius Health, INC. | $224.84 | 2024-2025 | Tymlos |
| Pfizer INC. | $218.62 | 2022-2025 | |
| Abbvie INC. | $185.98 | 2020-2024 | |
| Boston Scientific Corporation | $182.12 | 2024 | Watchman Flx |
| Eisai INC. | $175.35 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $170.21 | 2021 | |
| Glaxosmithkline, LLC. | $162.68 | 2022-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Exact Sciences Corporation | $146.31 | 2024-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $139.15 | 2024-2025 | Veozah |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $136.33 | 2024 | Voquezna |
| Idorsia Pharmaceuticals US INC | $135.06 | 2022-2023 | Quviviq |
| Merck Sharp & Dohme LLC | $122.66 | 2021-2025 | Capvaxive, Gardasil 9, Gardasil |
| Ucb, INC. | $122.56 | 2023 | |
| Amarin Pharma, INC. | $91.44 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $83.77 | 2020-2025 | Zoryve |
| Abbott Laboratories | $82.35 | 2022-2025 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $74.82 | 2020-2023 | Nexletol |
| Philips North America LLC | $66.70 | 2025 | Extended Holter, Holter |
| Biogen, INC. | $52.38 | 2021-2022 | |
| Inspire Medical Systems, INC. | $51.95 | 2023-2024 | Inspire |
| Xeris Pharmaceuticals, INC. | $42.36 | 2022 | |
| Daiichi Sankyo INC. | $24.60 | 2020 | |
| Sumitomo Pharma America, INC. | $17.87 | 2023 | Gemtesa |
| Janssen Pharmaceuticals, INC | $15.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zhao Han listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.